These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 11036292)

  • 41. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
    Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
    J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The role of FDG-PET scan in the diagnosis of pancreatic carcinoma].
    Papós M; Takács T; Pávics L; Farkas G; Ambrus E; Szakáll S; Lonovics J; Csernay L; Trón L
    Orv Hetil; 2002 May; 143(21 Suppl 3):1283-6. PubMed ID: 12077917
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Controlled prospective study of positron emission tomography using the glucose analogue [18f]fluorodeoxyglucose in the evaluation of pulmonary nodules.
    Präuer HW; Weber WA; Römer W; Treumann T; Ziegler SI; Schwaiger M
    Br J Surg; 1998 Nov; 85(11):1506-11. PubMed ID: 9823912
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of fluorodeoxyglucose and positron emission tomography in the evaluation of pancreatic disease.
    Rajput A; Stellato TA; Faulhaber PF; Vesselle HJ; Miraldi F
    Surgery; 1998 Oct; 124(4):793-7; discussion 797-8. PubMed ID: 9781003
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diagnostic impact of 18F-FDG PET-CT evaluating solid pancreatic lesions versus endosonography, endoscopic retrograde cholangio-pancreatography with intraductal ultrasonography and abdominal ultrasound.
    Schick V; Franzius C; Beyna T; Oei ML; Schnekenburger J; Weckesser M; Domschke W; Schober O; Heindel W; Pohle T; Juergens KU
    Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1775-85. PubMed ID: 18481063
    [TBL] [Abstract][Full Text] [Related]  

  • 46. F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer.
    Berlangieri SU; Scott AM; Knight SR; Fitt GJ; Hennessy OF; Tochon-Danguy HJ; Clarke CP; McKay WJ
    Eur J Cardiothorac Surg; 1999 Sep; 16 Suppl 1():S25-30. PubMed ID: 10536941
    [TBL] [Abstract][Full Text] [Related]  

  • 47. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Positron emission tomography does not add to computed tomography for the diagnosis and staging of pancreatic cancer.
    Lytras D; Connor S; Bosonnet L; Jayan R; Evans J; Hughes M; Garvey CJ; Ghaneh P; Sutton R; Vinjamuri S; Neoptolemos JP
    Dig Surg; 2005; 22(1-2):55-61; discussion 62. PubMed ID: 15838173
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diagnosis and staging of pancreatic cancer by positron emission tomography.
    Berberat P; Friess H; Kashiwagi M; Beger HG; Büchler MW
    World J Surg; 1999 Sep; 23(9):882-7. PubMed ID: 10449814
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
    Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
    Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fluorodeoxyglucose-positron emission tomography/computed tomography performs better than contrast-enhanced computed tomography for metastasis evaluation in the initial staging of pancreatic adenocarcinoma.
    Santhosh S; Mittal BR; Bhasin DK; Rana SS; Gupta R; Das A; Nada R
    Ann Nucl Med; 2017 Oct; 31(8):575-581. PubMed ID: 28689356
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Post-PET ultrasound improves specificity of 18F-FDG-PET for recurrent differentiated thyroid cancer while maintaining sensitivity.
    Biermann M; Kråkenes J; Brauckhoff K; Haugland HK; Heinecke A; Akslen LA; Varhaug JE; Brauckhoff M
    Acta Radiol; 2015 Nov; 56(11):1350-60. PubMed ID: 25770086
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparing the performance of visual estimation and standard uptake value of F-18 fluorodeoxyglucose positron emission tomography/computed tomography for detecting malignancy in pancreatic tumors other than invasive ductal carcinoma.
    Otomi Y; Otsuka H; Terazawa K; Nose H; Kubo M; Matsuzaki K; Ikushima H; Bando Y; Harada M
    J Med Invest; 2014; 61(1-2):171-9. PubMed ID: 24705763
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preoperative Assessment of Pancreatic Cancer with FDG PET/MR Imaging versus FDG PET/CT Plus Contrast-enhanced Multidetector CT: A Prospective Preliminary Study.
    Joo I; Lee JM; Lee DH; Lee ES; Paeng JC; Lee SJ; Jang JY; Kim SW; Ryu JK; Lee KB
    Radiology; 2017 Jan; 282(1):149-159. PubMed ID: 27556273
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cancer: a meta-analysis.
    Rijkers AP; Valkema R; Duivenvoorden HJ; van Eijck CH
    Eur J Surg Oncol; 2014 Jul; 40(7):794-804. PubMed ID: 24755095
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Simplified dual time point FDG-PET/computed tomography for determining dignity of pancreatic lesions.
    Bieg C; Mongelli F; Peterli R; Chirindel AF; Metzger J; von Flüe M; Gass M
    Nucl Med Commun; 2020 Jul; 41(7):682-687. PubMed ID: 32404649
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer.
    Adams S; Baum RP; Stuckensen T; Bitter K; Hör G
    Eur J Nucl Med; 1998 Sep; 25(9):1255-60. PubMed ID: 9724374
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis and management of pancreatic cancer; comparison with multidetector row computed tomography, magnetic resonance imaging and endoscopic ultrasonography.
    Ergul N; Gundogan C; Tozlu M; Toprak H; Kadıoglu H; Aydin M; Cermik TF
    Rev Esp Med Nucl Imagen Mol; 2014; 33(3):159-64. PubMed ID: 24140024
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Contribution of PET in the detection of liver metastases from pancreatic tumours.
    Nakamoto Y; Higashi T; Sakahara H; Tamaki N; Kogire M; Imamura M; Konishi J
    Clin Radiol; 1999 Apr; 54(4):248-52. PubMed ID: 10210345
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma.
    Frilling A; Tecklenborg K; Görges R; Weber F; Clausen M; Broelsch EC
    Ann Surg; 2001 Dec; 234(6):804-11. PubMed ID: 11729387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.